Several hospital groups recently sued the U.S. Department of Health and Human Services (HHS). This latest complaint asks the federal court to require HHS to issue rulemaking for 340B ceiling prices and accompanying penalties for manufacturers that fail to comply within 30 days of ruling. The plaintiffs in the lawsuit “collectively represent virtually every 340B […]
Several hospital groups recently refiled a lawsuit against the Trump Administration for cuts to the 340B Drug Discount Program under the Hospital Outpatient Prospective Payment System (OPPS) Final Rule for CY 2018. The litigation, led by the American Hospital Association, America’s Essential Hospitals and the Association of American Medical Colleges, alleges that 340B payment reductions […]
In keeping with the ongoing Congressional attention on everything related to pharmaceuticals, another bill aimed at improving the integrity of the 340B program – Stretching Entity Resources for Vulnerable (SERV) Communities Act or H.R. 6071 – was recently introduced in the House. In her press release, Representative Matsui (D-CA), the bill’s primary sponsor, stated the […]
The Senate Health, Education, Labor and Pensions (HELP) Committee recently held a hearing entitled, “Examining Oversight Reports on the 340B Drug Pricing Program” to coincide with the release of findings from the U.S. Government Accountability Office (GAO) regarding their efforts to improve oversight for the program. Most of the witness testimony focused on the lack […]
Read our latest specialty pharmacy insight report here.